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Pregnancy and obesity are frequently associated with diminished insulin sensitivity, which is normally compensated 
for by an expansion of the functional β cell mass that prevents chronic hyperglycemia and development of diabetes 
mellitus. The molecular basis underlying compensatory β cell mass expansion is largely unknown. We found in 
rodents that β cell mass expansion during pregnancy and obesity is associated with changes in the expression of 
several islet microRNAs, including miR-338-3p. In isolated pancreatic islets, we recapitulated the decreased miR-
338-3p level observed in gestation and obesity by activating the G protein–coupled estrogen receptor GPR30 and 
the glucagon-like peptide 1 (GLP1) receptor. Blockade of miR-338-3p in β cells using specific anti-miR molecules 
mimicked gene expression changes occurring during β cell mass expansion and resulted in increased proliferation 
and improved survival both in vitro and in vivo. These findings point to a major role for miR-338-3p in compensa-
tory β cell mass expansion occurring under different insulin resistance states.
Introduction
Diabetes mellitus is a metabolic disorder characterized by chronic 
hyperglycemia resulting from defective function and/or loss of 
insulin-secreting β cells (1, 2). These cells, located within the islets 
of Langerhans, display a slow turnover rate (3, 4). Conditions such 
as pregnancy and obesity are associated with a diminished sensi-
tivity of insulin target tissues and a consequent rise in the insu-
lin demand that is compensated for by an increase in the number 
and secretory activity of β cells (2, 5–7). Genetically predisposed 
individuals exposed to physiological or environmental conditions 
that trigger insulin resistance fail to compensate for the increased 
insulin demand and are prone to developing gestational and type 
2 diabetes (8). Detailed knowledge of the mechanisms controlling 
compensatory β cell mass expansion would allow a better under-
standing of the events underlying the development of gestational 
and type 2 diabetes and provide the basis for the design of new 
strategies to prevent and treat these diseases.
Pregnancy is the strongest physiological stimulus inducing 
β cell mass plasticity (9–11). In rodents, β cell mass expansion 
peaks at day 14 of gestation (9, 12) and occurs through a combi-
nation of mechanisms, including an increase in β cell replication 
and β cell hypertrophy and a minimal rate of β cell apoptosis (12). 
The mass of β cells and their secretory activity returns to prepreg-
nancy levels within the first 10 days after parturition (12, 13). Dif-
ferent mechanisms have been proposed to control adaptive β cell 
mass plasticity. Among these, the most thoroughly investigated 
are those elicited by prolactin and placental lactogen. In fact, 
pregnant mice lacking the prolactin receptor, which mediates the 
action of both lactogenic hormones, develop gestational diabetes 
(14). Lactogenic hormones trigger β cell mass expansion through 
different mechanisms, including reduction of Menin, a protein 
exerting an inhibitory action on insulin secretion and β cell pro-
liferation (15); induction of the transcription factor FoxM1 (16); 
and activation of a paracrine/autocrine loop leading to increased 
serotonin production by β cells (17, 18). At least some of these 
signaling cascades may not be restricted to pregnancy and may 
also operate during compensatory β cell proliferation associated 
with obesity (15, 19). Beside lactogenic hormones, additional 
factors have been proposed to contribute to adaptive changes in 
β cell mass, including steroid hormones and lipids (20, 21). So far, 
the mechanisms underlying the effect of these factors on β cell 
expansion are poorly understood.
microRNAs (miRNAs) are small noncoding RNAs acting as 
translational repressors that play a major role in the control of cell 
proliferation and survival. These regulatory molecules bind to the 
3′ untranslated region of target mRNAs, leading to translational 
inhibition and/or messenger degradation (22, 23). In pancreatic 
β cells, miRNAs govern the expression of key genes essential for 
insulin secretion and for cell survival (24–29). Several studies 
reported changes in the expression of islet miRNAs in animal 
models of diabetes with detrimental effects on the secretory activ-
ity and survival of β cells (30, 31). Moreover, leptin-deficient obese 
mice lacking miR-375 failed to compensate for insulin resistance 
and developed a severe diabetic phenotype (32). These observa-
tions prompted us to investigate whether changes in miRNA 
expression contribute to compensatory β cell mass expansion dur-
ing pregnancy. Our study led us to identify miRNAs regulated by 
estradiol and incretins that are differentially expressed in mater-
nal islets during pregnancy. Reduction of the level of one of these 
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miRNAs — miR-338-3p, which mimics the conditions observed 
during gestation — promoted β cell proliferation and protected 
the cells against apoptosis. Interestingly, the level of this miRNA 
was also reduced in the islets of other animal models characterized 
by β cell mass expansion, suggesting a general role for miR-338-3p 
in this important compensatory mechanism.
Results
Changes in miRNA expression in pancreatic islets during pregnancy. To 
identify miRNAs potentially involved in β cell mass expansion dur-
ing pregnancy, we analyzed by microarray the level of 350 miRNAs 
in islets of rats at day 14 of gestation (corresponding to the peak of 
β cell mass expansion; ref. 9) and age-matched nonpregnant female 
rats. Of the 203 miRNAs expressed at detectable levels in the islet 
preparations, 7 displayed changes at day 14 of gestation (Supple-
mental Table 1; supplemental material available online with this 
article; doi:10.1172/JCI64151DS1). Significant differences in the 
level of 5 of these miRNAs were confirmed by quantitative real-
time PCR (qRT-PCR; Figure 1A). miR-874, which was expressed at 
very low levels in the islets, as well as miR-325-5p and miR-188, 
whose changes were not confirmed by qRT-PCR (data not shown), 
were not investigated further. Of the 4 retained miRNAs, miR-218 
and miR-338-3p were downregulated, whereas miR-144 and miR-
451 were upregulated, at day 14. Analysis of the expression of these 
miRNAs at different stages of gestation revealed that the variations 
in expression correlated with the modifications in β cell mass, peak-
ing at day 14 and returning close to pregestational levels at the end 
of the pregnancy and at day 3 postpartum (Figure 1B).
Functional roles of the identified miRNAs in pancreatic islet cells. To 
determine the potential involvement of the selected miRNAs in the 
control of β cell functions, we mimicked the changes in expression 
observed during pregnancy by transfecting dissociated rat and 
human islet cells or the insulin-secreting cell lines INS832/13 and 
MIN6B1 with oligonucleotides that either specifically block (anti-
miR) or increase (oligonucleotide mimic) the level of the miRNAs. 
The efficacy of these treatments was verified by qRT-PCR (Supple-
mental Figure 1). We first assessed whether changes in expression 
mimicking those observed during pregnancy affect glucose-stim-
ulated insulin secretion. Inhibition of miR-218 and miR-338-3p 
or overexpression of miR-144 and miR-451 in dissociated rat islet 
cells and MIN6 cells did not significantly alter insulin content 
(Supplemental Figure 2). Moreover, insulin release under basal 
conditions and upon glucose stimulation was unaffected (Sup-
plemental Figure 2). Next we investigated whether the miRNAs 
contribute to the regulation of β cell proliferation. Changes in 
the level of miR-218, miR-144, and miR-451 did not significantly 
modify the number of Ki67+ or BrdU+ INS832/13 cells (Figure 2, A 
and B). In contrast, reduction of miR-338-3p expression led to an 
increase in the number of proliferating INS832/13 cells (Figure 2, 
A and B). Analogous effects were observed in dissociated rat islet 
cells (Figure 2C). In contrast, modulation of the 4 miRNAs did not 
significantly change pancreatic α cell proliferation (Supplemental 
Figure 3). To verify that the reduction of miR-338-3p also retains 
proproliferative properties in vivo, dissociated rat islet cells trans-
fected with anti–miR-338-3p were cultured for 2 days to induce 
pseudoislet aggregate formation, then transplanted under the rat 
kidney capsule. We found that blockade of miR-338-3p resulted 
in an approximately 80% increase in proliferating insulin+ cells 
(Figure 2D). Proliferation of glucagon+ cells was again unaffected 
(Figure 2D). The effect of miR-338-3p downregulation on prolif-
eration was also tested in human β cells. However, in line with the 
data available in the literature (33, 34), neither different hormones 
capable of triggering proliferation of rodent β cells nor miR-338-
3p downregulation were capable of eliciting replication of human 
β cells (Supplemental Table 2).
β cell mass expansion during pregnancy is thought to result 
from an increase in proliferation combined with a low apoptotic 
rate. To explore a possible involvement of the miRNAs in apop-
tosis, dissociated rat and human islet cells were transfected with 
anti–miR-218 and anti–miR-338-3p or with oligonucleotides that 
cause miR-144 and miR-451 overexpression. The cells were then 
incubated in the presence of proinflammatory cytokines, includ-
Figure 1
Identification of miRNAs differentially expressed in the islets of preg-
nant rats. (A) Expression of the indicated miRNAs was measured by 
qRT-PCR in the islets of female rats at day 14 of gestation. Results 
are expressed as fold changes and correspond to the mean ± SD of 4 
nonpregnant (NP) control and 4 pregnant rats. (B) Expression of the 
indicated miRNAs was determined by qRT-PCR in islets from nonpreg-
nant rats and from pregnant rats at days 10, 12, 14, and 20 of gestation 
(G10, G12, G14, and G20, respectively) and 3 days postpartum (P3). 
Results (mean ± SD of 4 animals per group) are expressed as percent 
of the level of each miRNA in nonpregnant rats. *P < 0.05 vs. nonpreg-
nant, ANOVA.
Downloaded on December  4, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/64151
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012 3543
ing IL-1β, TNF-α, and IFN-γ. As expected (35, 36), prolonged expo-
sure to cytokines triggered β cell apoptosis while the number of 
necrotic cells remained stable (Figure 3). Anti–miR-338-3p treat-
ment and miR-451 overexpression in rat islet cells resulted in a 
striking reduction in cytokine-induced apoptosis, as assessed by 
annexin V staining and by counting the cells displaying picnotic 
nuclei (Figure 3, A and B). The protective effect of miR-338-3p 
downregulation and miR-451 overexpression was not selective 
for cytokines and was also observed when apoptosis was triggered 
by incubating rat islet cells with palmitate (Figure 3C). Similar 
data were obtained with dissociated human islet cells exposed to 
cytokines (Figure 3D). Overexpression of miR-338-3p in dispersed 
rat islet cells led to an increase in apoptosis (Figure 3E), which 
confirmed the involvement of this miRNA in cell survival. Taken 
together, these findings support the idea that changes in the level 
of miR-338-3p and miR-451 can contribute to adaptive β cell mass 
plasticity that occurs during pregnancy.
17-β estradiol downregulates miR-338-3p expression by activating GPR30 
signaling. Pregnancy is characterized by a plasmatic increase in 
maternal hormones, including prolactin (PRL), progesterone, and 
17-β estradiol (37). To gain insight into the mechanisms regulating 
the expression of the selected miRNAs, islets and insulin-secreting 
cell lines were exposed for 48 hours to these maternal hormones. 
We found that prolactin (which is known to trigger β cell prolif-
eration; refs. 20, 38), and progesterone did 
not affect miR-338-3p levels in INS832/13 
cells (data not shown). PRL was also with-
out effect on miR-218, miR-144, and miR-
451 (data not shown). Estrogens have anti-
apoptotic and proproliferative effects on 
β cells (20, 39–41). Exposure to 100 nM 17-β 
estradiol reduced by about half the level of 
miR-338-3p in INS832/13 cells (data not 
shown) and in rat and human islet cells 
(Figure 4, A and B). A similar decrease was 
observed upon incubation at lower estra-
diol concentrations, namely, 1 or 10 nM 
(data not shown). Treatment of rat islets 
with 17-β estradiol did not affect miR-218 
and miR-451, but significantly upregulated 
miR-144 (Supplemental Figure 4). Similar 
results were obtained with human islets 
(data not shown). Overexpression of miR-
338-3p prevented the increase in proliferat-
ing INS832/13 cells and primary rat β cells 
elicited by 17-β estradiol (Figure 4, C and D), 
which indicates that a reduction in the level 
of this miRNA is required for the prolifera-
tive effect of the hormone.
Estrogens exert their action either by bind-
ing to conventional ERα/β receptors or by 
activating the G protein–coupled receptor 
GPR30 (40, 42–45). This transmembrane 
receptor is coupled to Gs and triggers a rise 
in cAMP and activation of the PKA signal-
ing cascade (46). We found that miR-338-
3p expression was downregulated upon 
exposure of rat islet cells to dibutyryl cAMP 
(Figure 5A). Moreover, treatment of dis-
persed rat or human islet cells with the PKA 
inhibitor H89 prevented the effect of 17-β estradiol on miR-338-3p 
expression (Figure 5, B and C), suggestive of a possible involvement 
of GPR30. We found that the expression of GPR30 increased dur-
ing pregnancy, peaking at day 14 of gestation and returning close 
to basal level at the end of gestation (Figure 5D). To directly assess 
whether estrogens control the level of miR-338-3p via activation of 
GPR30, rat islets were incubated with the GPR30 agonist G1 (47). 
Indeed, G1 treatment reduced miR-338-3p levels by about 35% (Fig-
ure 5E). Moreover, siRNAs directed against GPR30 were able to pre-
vent the decrease of miR-338-3p elicited by 17-β estradiol (Figure 5, 
F and G). Similar results were obtained when GPR30 activation in 
rat islet cells was blocked using the specific antagonist G15 (data 
not shown). In contrast, Fulvestrant (ICI 182-780), an antagonist 
of conventional ERα/β receptors, did not affect estradiol-induced 
miR-338-3p downregulation (Figure 5H).
Downstream signaling elicited by miR-338-3p downregulation. Since 
miR-338-3p appears to play an important role in the control of 
β cell mass expansion, we searched for its molecular target(s). Dur-
ing pregnancy, several key genes known to regulate β cell prolifera-
tion and/or survival displayed expression profiles that were inverse-
ly correlated to the level of miR-338-3p (Figure 6A). Blockade of 
miR-338-3p in dissociated rat or human islet cells was sufficient to 
mimic several of the changes occurring during pregnancy, includ-
ing an increase of Birc5, Igf1r, Irs2, Bcl2, and Bcl-xl and a decrease of 
Figure 2
Effect of miRNA level modification on β cell proliferation. (A and B) INS832/13 cells were 
transfected with a scrambled anti-miR (anti-ctrl) or with anti-miR specifically blocking miR-218 
or miR-338-3p (left), or with oligonucleotides leading to miR-144 or miR-451 overexpression 
or an siRNA directed against siGFP as control (right). (C) Dissociated rat islet cells were trans-
fected with anti-miRs (left) or oligonucleotide mimics (right) to modulate the expression of the 
indicated miRNAs. Cells treated with prolactin (500 ng/ml for 48 hours) were used as positive 
control for proliferation. The fraction of proliferating insulin+ cells was assessed by scoring Ki67+ 
(A and C) or BrdU+ (B) cells. Data are mean ± SD of 6 independent experiments. *P < 0.05 vs. 
control, ANOVA. (D) Dissociated rat islet cells were transfected with a scrambled anti-miR or 
with anti–miR-338-3p. They were then cultured for 2 days to induce formation of pseudoislet 
aggregates and transplanted under the renal capsule of congenic rats. 3 days later, the fraction 
of proliferating β (left) and α (right) cells in the transplanted islets was assessed by scoring 
the insulin+ or glucagon+ cells incorporating BrdU, respectively. Results are mean ± SD of 3 
independent experiments. *P < 0.05 vs. control, ANOVA.
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Bad (Figure 6, B and C). For Birc5, Igf1r, and Bcl2, which displayed 
the most striking variations in response to miR-338-3p blockade, 
the changes observed at the mRNA level were confirmed at the pro-
tein level (Supplemental Figure 5). Any of these genes are predicted 
targets of miR-338-3p (http://www.targetscan.org/), and they are 
probably not directly controlled by the miRNA. The phenotypic 
changes observed most likely result from the effect of miR-338-
3p on multiple genes and not from the effect of the miRNA on a 
single target. Thus, instead of searching for individual targets, we 
attempted to obtain a global picture of the genes affected by miR-
338-3p by performing transcriptomic analysis of INS832/13 cells 
in which miR-338-3p was downregulated. Bioinformatic analysis 
of the 699 genes differentially expressed in cells with reduced miR-
338-3p level revealed an enrichment of genes involved in cell cycle 
and cell growth (Supplemental Table 3).
miR-338-3p downregulation occurs in the islets of other animal models 
displaying β cell mass expansion. To assess whether reduction of miR-
338-3p is a general phenomenon associated with increases in β cell 
mass, we measured the level of this miRNA in the islets of 2 ani-
mal models characterized by insulin resistance and compensatory 
β cell mass expansion. We first measured miR-218, miR-338-3p, 
miR-144, and miR-451 expression in islets of mice fed a high-fat 
diet (HFD) for 8 weeks. These mice are obese, hyperinsulinemic, 
and glucose intolerant and display increased β cell mass (48). In 
HFD-fed mice, the level of miR-218 and miR-144 were unchanged, 
whereas expression of miR-451 was increased by 60% ± 36% 
(P < 0.05; n = 4). In the islets of these mice, expression of miR-338-
3p decreased 2- to 3-fold compared with mice fed a normal diet 
(Figure 7A). In the islets of 6-week-old db/db mice, which lack the 
leptin receptor (49), expression of miR-338-3p was also reduced by 
about 80% (Figure 7B). In contrast, the level of the other 3 miRNAs 
was unaffected (data not shown). At this age, db/db mice are obese, 
but still normoglycemic. These findings indicate that changes in 
miR-338-3p expression are not restricted to pregnancy, but also 
occur in other physiopathological conditions characterized by 
insulin resistance and compensatory β cell mass expansion.
miR-338-3p levels are controlled by incretins. GPR30 expression is 
unchanged in the islets of diet-induced obese mice and db/db mice 
(Supplemental Figure 6). In view of these findings, estrogens are 
unlikely to mediate the decrease in miR-338-3p observed in obese 
Figure 3
Inhibition of miR-338-3p protects β cells against 
apoptosis. Dissociated rat (A–C and E) and 
human (D) islet cells were transfected with 
anti-miRs (left) or oligonucleotide mimics (right) 
to modulate the expression of the indicated 
miRNAs. Cells were incubated for 24 hours with 
or without a mix of proinflammatory cytokines 
(10 ng/ml TNF-α, 0.1 ng/ml IL-1β, 30 ng/ml IFN-γ; 
A, B, D, and E) or for 48 hours either with 0.5% 
BSA or with 0.5% BSA coupled to 0.5 mmol/l 
palmitate (C). Apoptosis was assessed either by 
labeling the cells with annexin V (A) or by stain-
ing picnotic nuclei (B–E). Annexin V and prop-
idium iodide staining allowed for assessment of 
apoptosis (gray bars) and necrosis (black bars), 
respectively. Data are mean ± SD of 4 indepen-
dent experiments. *P < 0.05, ANOVA.
Downloaded on December  4, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/64151
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012 3545
mice. Therefore, we searched for other signaling pathways poten-
tially regulating the expression of the miRNA. The incretin gluca-
gon-like peptide 1 (GLP1) is known to promote β cell proliferation 
and to protect the cells against apoptosis through a cAMP-depen-
dent mechanism (50, 51). We found that exposure of rat or human 
islets to the GLP1 analog exendin-4 decreased the level of miR-338-
3p by about 2.5-fold (Figure 8, A and B). miR-144 and miR-451 
expression were increased by exendin-4 treatment, whereas miR-
218 was unaffected by the GLP1 analog (Supplemental Figure 7). 
In the islets of Glp1r–/–Gip1r–/– mice, which display elevated rates 
of β cell death and impaired insulin secretion (52), this miRNA 
was upregulated about 2.3-fold (Figure 8C), in agreement with an 
involvement of incretins in the control of miR-338-3p expression.
The beneficial effects of GLP1 on β cell function relies on an 
autocrine loop involving the upregulation of Igf1r and Irs2. As 
mentioned above, blockade of miR-338-3p mimicked this effect of 
GLP1 and led to an increase of Igf1r and Irs2 expression (Figure 6, 
B and C). In addition, we found that overexpression of miR-338-3p 
prevented the induction of Igf1r and Irs2 (Figure 8D) and the rise 
in proliferation observed in response to exendin-4 (Figure 8, E and 
F). Taken together, these results strongly support the hypothesis 
of miR-338-3p involvement in the effects of incretins on β cells.
Discussion
miRNAs are small noncoding RNAs that play important roles in 
the regulation of β cell function, including proliferation and sur-
vival (27, 32). To our knowledge, their potential involvement in 
compensatory β cell expansion had not previously been investi-
gated. The present study revealed changes in the expression of a 
subset of islet miRNAs that correlate with the adaptation of β cell 
mass during different stages of rat pregnancy. In fact, the peak of 
β cell mass expansion at day 14 of gestation corresponded to maxi-
mal upregulation of miR-144 and miR-451 and maximal down-
regulation of miR-218 and miR-338-3p. These expression changes 
were reversed at the end of pregnancy, when β cell mass returned to 
pregestation levels. At least part of these modifications in miRNA 
expression caused adaptations in cellular functions, with a poten-
tial effect on islet β cell number. Indeed, miR-338-3p downregula-
tion promoted proliferation and protected rat β cells against apop-
tosis, and a rise of miR-451 was associated with improved resistance 
of rat β cells to proapoptotic stimuli. Conversely, upregulation of 
miR-338-3p triggered apoptosis, mimicking the reduction of β cells 
observed at the end of pregnancy (13). The effect on apoptosis was 
also confirmed in human β cells, but anti–miR-338-3p treatment 
was not sufficient to trigger replication of these cells. This result 
was somehow expected, because proliferation of human β cells is 
an extremely rare event (33, 34); even exendin, estradiol, and the 
GRP30 ligand G1, which are capable of decreasing miR-338-3p 
expression under the same experimental conditions, failed to elicit 
proliferation. Thus, the potential role of miR-338-3p on human 
β cell proliferation will need to be reevaluated once better approach-
es to assess replication of these cells are developed.
Interestingly, knockdown of miR-338-3p triggered proliferation 
of rat β cells, but not of α cells. The precise causes of this cell-selec-
tive effect will need to be addressed in future studies. The global 
miRNA expression profile of primary α and β cells is not yet avail-
able, and it is possible that miR-338-3p is expressed at different lev-
els in glucagon-secreting cells than in insulin-secreting cells or that 
the function of this miRNA is counterbalanced by other miRNAs. 
Another attractive possibility is that the signaling pathways 
elicited upon miR-338-3p downregulation are not operating in 
α cells. Indeed, we showed that at least part of the effect of anti–
miR-338-3p on β cells was mediated through induction of Igf1r, a 
receptor that seems to not be involved in α cell proliferation (53).
Despite these proliferative and antiapoptotic effects, miR-338-3p 
downregulation and miR-451 overexpression did not significant-
ly affect insulin content and glucose-induced insulin secretion, 
which indicates that upon changes in the level of these miRNAs, 
the β cells retained a fully differentiated phenotype. Taken togeth-
er, these results are consistent with these miRNAs contributing to 
maternal adaptations in β cell mass that occur during gestation. 
Modulation of the level of miR-218 or miR-144 in vitro did not 
Figure 4
miR-338-3p is downregulated by 17-β estradiol, and its overexpression impairs the proliferative effect of the hormone. miR-338-3p expression 
was measured in rat (A) and human (B) islets incubated with vehicle control or with 100 nM estradiol (E2) for 48 hours. INS832/13 cells (C) and 
dispersed rat islet cells (D) were transfected with a control oligonucleotide or with an oligonucleotide leading to miR-338-3p overexpression. Cells 
were then incubated for 48 hours in the presence or absence of 100 nM estradiol or 100 nM G1. Proliferation was assessed by scoring the frac-
tion of BrdU+ (C) or Ki67+ (D) cells. Data are mean ± SD of 5 (C) or 6 (D) independent experiments. *P < 0.05 vs. control, #P < 0.05 vs. estradiol 
or G1 alone, ANOVA.
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result in detectable modifications in the activities of rat islet cells 
or INS832/13 cells. However, a contribution of these miRNAs to 
β cell adaptation in vivo cannot be excluded at this stage.
In view of its multiple effects on β cell activities, we attempted 
to elucidate the mode of action of miR-338-3p. Blockade of this 
miRNA had a strong effect on a set of genes playing key roles in β cell 
proliferation and survival. Birc5 (also known as Survivin) and Foxm1 
were among the most interesting genes upregulated in β cells upon 
blockade of miR-338-3p: the former has antiapoptotic and propro-
liferative properties, and the latter promotes β cell proliferation (19, 
54). Both have been shown to increase in islets from animal models 
characterized by β cell expansion and regeneration, such as pregnant 
mice at day 14 of gestation and ob/ob mice (16, 19, 55). Other adap-
tations in gene expression consistent with the increased proliferative 
capacity and improved survival of β cells included elevated levels of 
Igf1r and Irs2 and a rise in the antiapoptotic protein Bcl2.
Compensatory β cell mass expansion during pregnancy is 
thought to be triggered by an increase in maternal hormones. Lac-
togens are generally recognized as key inducers of this process (15, 
17, 56). Indeed, pregnant mice lacking the prolactin receptor, which 
mediates the action of lactogenic hormones, develop gestational 
diabetes (14). Despite increasing plasmatic levels of estradiol dur-
ing pregnancy and the capacity of this hormone to increase replica-
tion and improve survival and function of insulin-secreting cells in 
vitro and in vivo (20, 37, 40, 57), the contribution of estrogens to 
adaptive β cell mass expansion had thus far remained elusive. Our 
study unveiled a possible role for estradiol in pregnancy-associated 
β cell mass expansion through repression of miR-338-3p. Reduc-
tion of miR-338-3p level in rat islet cells mimicked the phenotypic 
changes observed upon estradiol treatment and, conversely, over-
expression of miR-338-3p prevented estradiol-induced prolifera-
tion. Our data indicate that the effect of estradiol is not mediated 
Figure 5
17-β estradiol controls miR-338-3p expression through activation of GPR30. (A–C and E–H) miR-338-3p levels were assessed by qRT-PCR 
and expressed as a percentage of U6. Rat islets were (A) cultured in the presence of 1 mM dibutyryl cAMP for 0 (Ctrl), 2, 6, and 24 hours; (B) 
treated for 24 hours with or without 100 nM 17-β estradiol in the presence or absence of 10 μM H89; (E) incubated for 16 hours with vehicle or 
100 nM G1; (F) transfected with siRNAs directed against GFP or GPR30, and the following day incubated with or without estradiol for 48 hours; 
or (H) cultured for 24 hours with 100 nM 17-β estradiol in the presence or absence of 100 nM Fulvestrant. (C) Human islets treated as in B. (G) 
INS832/13 cells transfected as in F. (D) Expression of GPR30 in islets from nonpregnant rats and of rats at 10, 12, 14, and 20 days of pregnancy 
and 3 days postpartum. Results are expressed as fold change compared with the level in nonpregnant rats. Data are mean ± SD (n = 3 [A and 
C]; 4 [B, D, E, G, and H]; 5 [F]). *P < 0.05 vs. control, #P < 0.05 vs. estradiol, ANOVA.
Downloaded on December  4, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/64151
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 122   Number 10   October 2012 3547
through conventional ERα/β receptors, but rather occurs through 
activation of GPR30 (46, 58, 59). In fact, the effect of estradiol was 
cAMP-dependent and was blocked by PKA inhibitors. Moreover, 
the reduction of miR-338-3p expression observed upon estradiol 
treatment was mimicked by a GPR30 agonist, and silencing of the 
receptor by RNA interference eliminated the effect of the hormone. 
Moreover, GPR30 expression was strongly upregulated during 
pregnancy and correlated with β cell mass expansion. Thus, the 
effect of estradiol is likely to be restricted to pregnancy, and miR-
338-3p levels are probably not influenced by the fluctuations of 
this hormone during oestrus. GPR30 knockout mice display altera-
tions in blood glucose homeostasis (42, 60), but the potential role 
of this receptor in the control of β cell mass in vivo has not been 
investigated. Because of the broad tissue expression of GPR30, a 
definitive assessment of the contribution of this receptor in com-
pensatory β cell mass expansion during pregnancy will necessitate 
the generation of β cell–specific knockouts.
A mechanism analogous to the one we uncovered for compensa-
tory β cell mass expansion during pregnancy is likely to operate 
in other conditions characterized by insulin resistance, such as 
obesity. Indeed, miR-338-3p was downregulated in young predia-
betic db/db mice and in HFD-fed mice. Injection of estradiol in 
Zucker diabetic fatty rats has previously been reported to prevent 
β cell death by suppressing lipid synthesis in insulin-secreting 
cells (61). However, it is unlikely that the reduction in miR-338-
3p expression in obese animals is mediated by GPR30, because 
GPR30 mRNA levels were unchanged in the islets of HFD-fed 
mice. Additional experiments will be required to completely rule 
out a contribution of GPR30 to β cell mass compensation in obe-
sity models. Because GPR30 is expressed in several tissues, and 
general knockout mice display metabolic perturbations (42, 62), 
the generation of β cell–specific GPR30 knockout mice will be 
required to assess the role of GPR30 in compensatory β cell mass 
expansion in obesity models. Our data suggest that in nonpreg-
nant animals, the level of miR-338-3p may be controlled by incre-
tins. GLP1 was able to downregulate miR-338-3p expression in 
isolated rat islet cells. Moreover, the level of miR-338-3p was sig-
nificantly increased in the islets of Glp1r–/–Gip1r–/– mice. A recent 
study demonstrated IL-6–induced production of GLP1 by α cells 
in pancreatic islets of HFD-fed mice (63). This obesity-induced 
adaptation process triggered by local production of GLP1 was 
fully compatible with the miRNA-dependent mechanism of β cell 
mass expansion described herein. The beneficial effects elicited 
by GLP1 on β cells rely on the activation of an autocrine loop 
that results in a rise in Igf1r and Irs2 (52). These key events in the 
signaling cascade triggered by GLP1 could be reproduced by miR-
338-3p downregulation. Moreover, overexpression of this miRNA 
Figure 6
miR-338-3p inhibition elicits gene 
expression changes analogous to 
those observed in islets of pregnant 
rats. (A) Birc5, Foxm1, Cyclin D2, 
Igf1r, Irs2, Bcl2, Bcl-xl, and Bad 
expression in islets of pregnant rats 
at different stages of gestation were 
measured by qRT-PCR. Results are 
presented as fold changes com-
pared with nonpregnant rats and 
represent mean ± SD of 4 rats per 
group. Rat (B) and human (C) islet 
cells were transfected with anti–
miR-338-3p. Birc5, Igf1r, Irs2, Bcl2, 
Bcl-xl, and Bad expression were 
measured by qRT-PCR and com-
pared with the level in cells trans-
fected with a scrambled anti-miR. 
Data are expressed as fold changes 
and represent mean ± SD of 4 (B) 
or 3 (C) independent experiments. 
*P < 0.05 vs. control, ANOVA.
Figure 7
miRNA expression in islets from HFD-fed and db/db mice. miR-338-
3p levels were measured by qRT-PCR in islets from HFD-fed mice for 
8 weeks (A) and in 6-week-old normoglycemic db/db mice (B). Data 
(mean ± SD of 4 different mice per group) are expressed as percent of 
U6. *P < 0.05 vs. control, ANOVA.
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prevented the increase in Igf1r and Irs2 and the enhanced prolifer-
ation rate observed in the presence of GLP1, which suggests that 
a reduction in miR-338-3p level is an important requirement for 
incretins to achieve full beneficial effects on β cells. Our observa-
tions indicate that the adaptive changes in β cell mass in response 
to insulin resistance associated with pregnancy and obesity are 
activated through distinct receptors, but that the downstream 
signaling pathways they elicit converge and culminate in overlap-
ping modifications in gene expression. Other factors known to 
induce β cell proliferation, such as pituitary adenylate cyclase–
activating polypeptide (PACAP; ref. 64) and glucose (65, 66), trig-
ger a rise in cAMP levels. Thus, it is tempting to speculate that at 
least part of the proliferative effects of these molecules may be 
achieved by reduction of miR-338-3p expression.
In conclusion, we here unveiled an analogy between the effects 
of estrogens and incretins on a subset of miRNAs involved in com-
pensatory β cell mass expansion occurring during pregnancy and 
obesity. Our findings have relevant implications for understand-
ing the physiological adaptation of β cells to increased insulin 
demand. Detailed knowledge of the mechanisms controlling the 
level and activity of the miRNAs differentially expressed during 
pregnancy may open the way to new therapeutic strategies, with 
the ultimate goal being to prevent and treat diabetes by promoting 
β cell mass regeneration.
Methods
Chemicals. Prolactin, 17-β estradiol, progesterone, H89, G1, ICI 182-780 
(Fulvestrant), dibutyryl cAMP, IL-1β, IL-6, palmitate, and exendin-4 were 
obtained from Sigma-Aldrich. TNF-α was obtained from Enzo Life Sci-
ences, and IFN-γ was from R&D Systems.
Animals. Male, female, and pregnant Wistar rats were obtained from 
Charles River Laboratories. The sources of db/db, HFD-fed, and Glp1r–/– 
Gip1r–/– mice have been described previously (48, 49, 52).
Gene expression analysis. Total RNA was isolated with the miRNeasy kit 
(Qiagen). Measurements of mature miRNA levels were carried out by qRT-
PCR using the miRCURY LNA Universal RT microRNA PCR kit (Exiqon). 
Determination of mRNA levels was achieved by conventional qRT-PCR 
using Bio-Rad Sybr Green reagent (Bio-Rad Laboratories). miRNA expres-
sion was normalized to levels of U6 small nuclear ribonucleoprotein or to 
the level of miR-7. mRNA expression was normalized to the amount of 18S 
present in the same samples.
miRNA profiling was performed at the Genomic Technologies Facility 
of the University of Lausanne using Agilent Technologies miRNA Gene 
Microarrays. The dataset is available from the GEO database (accession 
no. GSE36067). To assess the global effect of miR-338-3p knockdown 
on mRNA expression, total RNA from INS832/13 cells was analyzed at 
the Genomic Technologies Facility using the RaGene V1.0 Affymetrix 
GeneChip. Expression values were normalized using RMA expression sum-
mary algorithms (67) implemented in R (version 2.9.2) within the Affyme-
Figure 8
Incretins signaling and miR-338-3p regulation. Rat (A) or human (B) islets were incubated with or without 100 nM exendin-4 for 48 hours. miR-
338-3p expression was then measured by qRT-PCR. (C) miR-338-3p expression was assessed by qRT-PCR in islets of wild-type and Glp1r–/–
Gip1r–/– mice. Results in A–C are expressed as percentage of U6. (D) Rat islet cells were transfected with a control oligonucleotide (white bars) 
or with an oligonucleotide leading to miR-338-3p overexpression (black bars). Igf1r and Irs2 expression were quantified by qRT-PCR. Results are 
mean ± SD of 4 independent experiments. *P < 0.05 vs. control, ANOVA. INS832/13 cells (E) and dispersed rat islet cells (F) were transfected 
with a control oligonucleotide or with an oligonucleotide leading to miR-338-3p overexpression. Cells were incubated in the absence or presence 
of 100 nM exendin-4 for 48 hours. Proliferation was assessed by scoring the fraction of BrdU+ (E) or Ki67+ (F) cells. Data are mean ± SD (n = 5 
[E]; 6 [F]). *P < 0.05 vs. control, #P < 0.05 vs. exendin-4, ANOVA.
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the kidney bearing the graft was recovered and fixed in 10% neutral-buff-
ered formalin (Sigma-Aldrich) for 3 days and then embedded in paraffin. 
The kidneys were sectioned, rehydrated, and incubated with the follow-
ing primary antibodies: 1:20 mouse anti-BrdU (Roche), 1:200 guinea pig 
anti-insulin (Dako), 1:200 rabbit anti-glucagon (Dako). Cell nuclei were 
stained with Hoechst 33342. A minimum of 3,000 insulin+ cells per kidney 
was scored with a Zeiss Axiovision fluorescence microscope.
Cell death assessment. Dissociated rat islet cells were plated on poly-l-ly-
sine–coated glass coverslips and stained simultaneously with Annexin 
V–EGFP, propidium iodide, and Hoechst 33342 (Invitrogen) using the 
Annexin V–EGFP Apoptosis Detection kit (Biovision). At least 400 cells 
were analyzed for each condition, by scoring the apoptotic cells (Annexin 
V–EGFP with or without propidium iodide–positive cells) and necrotic 
cells (propidium iodide–positive cells). Alternatively, apoptosis was deter-
mined by scoring the cells displaying picnotic nuclei upon 10 minutes 
incubation at room temperature with Hoechst 33342 (Invitrogen). At least 
5 fields (about 400 cells) were analyzed for each condition.
Western blot analysis. INS832/13 cells were incubated for 15 minutes 
on ice in lysis buffer (20 mM Tris, 2 mM EDTA, and protease inhibitors 
[Roche]). They were then collected, briefly sonicated, and centrifuged to 
eliminate nuclei and cell debris. The proteins in the supernatants were 
separated by gel electrophoresis and transferred on PVDF membranes. 
The membranes were first incubated for 2 hours in blocking buffer (0.1% 
Tween 20 and 5% BSA [Sigma-Aldrich]), then overnight with the follow-
ing antibodies: 1:1,000 anti-Birc5 (Cell Signaling); 1:1,000 anti-Bcl2 (Cell 
Signaling); 1:2,000 rabbit anti-IGF1R (Cell Signaling); 1:20,000 anti-actin 
(Millipore); 1:14,000 anti-tubulin (Santa Cruz Biotechnology Inc.). Immu-
noreactive bands were visualized by chemiluminescence (Amersham Bio-
sciences) after 1 hour incubation with horseradish peroxidase–conjugated 
anti-rabbit and anti-mouse antibodies (Merck). The band intensity was 
quantified using ImageJ software.
Statistics. Statistical significance was tested by ANOVA followed by 
post-hoc Bonferroni test (Dunnett’s test) when experiments included 
more than 2 groups. The level of significance was set at P < 0.05 (SAS 
statistical package; SAS).
Study approval. All procedures with animals were performed in accor-
dance with NIH guidelines and were approved by the Cantonal Veterinary 
Office. The use of human islets for research was approved by the Geneva 
local institutional ethical committee.
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trix package (68). Statistical analysis was performed with Limma package 
(69). Probe sets with a q value less than 0.05 were considered differentially 
expressed with respect to anti–miR-control. The dataset is available from 
the GEO database (accession no. GSE36067). Biological function and 
pathway analyses were performed using DAVID (70).
Cell culture. The rat insulin-secreting cell line INS832/13 and the mouse 
insulin-secreting cell line MIN6B1 were cultured as described previously 
(71, 72). Rat pancreatic islets were isolated by collagenase digestion (73) 
and then purified on a Histopaque density gradient. They were cultured 
in RPMI 1640 Glutamax medium (Invitrogen) supplemented with 10% 
FCS, 50 U/ml penicillin, 50 μg/ml streptomycin, and 1 mM sodium 
pyruvate. Human pancreatic islets were provided by the Cell Isolation 
and Transplantation Center (University of Geneva, Geneva, Switzerland) 
thanks to the European Consortium for Islet Transplantation “Islets 
for Research” distribution program sponsored by the Juvenile Diabetes 
Research Foundation. Human islets were cultured in CMRL 1066 medi-
um (Invitrogen) supplemented with 10% FCS, 100 U/ml penicillin, 2 mM 
l-glutamine, and 25 μM HEPES.
Cell transfection. Before transfection, rat and human islets were dis-
sociated by trypsinization and cultured overnight. Dissociated rat and 
human islet cells, INS832/13 cells, and MIN6 cells were transiently 
transfected for 48 hours with anti-miR oligonucleotides that specifi-
cally block miRNA activity (Qiagen), or with oligonucleotide duplexes 
mimicking the mature sequence of the miRNAs (Eurogentec) using 
Lipofectamine 2000 (Invitrogen). A scrambled anti-miR and an siRNA 
duplex directed against GFP were used as controls. A pool of 4 siRNAs 
was used to knock down GPR30 expression (ON-TARGET plus SMART 
pool; Fisher Scientific).
Insulin secretion. Dissociated rat islet cells and MIN6B1 cells were prein-
cubated with KREBS buffer (127 mM NaCl, 4.7 mM KCl, 1 mM CaCl2, 
1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES, 5 mM NaHCO3) con-
taining 2 mM glucose (basal condition) for 30 minutes at 37°C. The 
medium was then replaced by either the same buffer (basal condition) or a 
KREBS buffer supplemented with 20 mM glucose (stimulatory condition). 
After 45 minutes, supernatants were collected, and cellular insulin con-
tents were recovered in EtOH acid (75% EtOH, 0.55% HCl). The amount 
of insulin in the samples was determined by ELISA (Chemie Brunschwig).
Immunocytochemistry. Dissociated rat islet cells or INS832/13 cells were 
plated on poly-l-lysine–coated glass coverslips. For BrdU incorporation 
assays, INS832/13 cells were exposed to BrdU (Roche) for the last 4 hours 
of culture. The cells were fixed in cold methanol and incubated with PBS 
supplemented with 0.5% saponin (Sigma-Aldrich) for 15 minutes. They 
were then incubated for 30 minutes in blocking buffer (PBS supplemented 
with 0.5% saponin and 1% BSA) and exposed for 1 hour at room tempera-
ture to primary antibodies at the following dilutions: 1:1,500 rabbit anti-
Ki67 (Abcam); 1:1,400 mouse anti-BrdU (Cell Signaling); 1:500 guinea pig 
anti-insulin (Millipore). The coverslips were then incubated for 1 hour at 
room temperature with goat anti-rabbit Alexa Fluor 488, goat anti-mouse 
Alexa Fluor 555, and goat anti–guinea pig Alexa Fluor 594 diluted at 1:400 
(Invitrogen). Finally, the cells were incubated for 10 minutes with Hoechst 
33342 (Invitrogen) and mounted on microscope glass slides with Fluor-
Save mounting medium (VWR International SA). Slides were visualized 
with a Zeiss Axiovision fluorescence microscope or with a Leica SP5 AOBS 
confocal microscope.
Islet transplantation. Dissociated rat islet cells were transfected with a 
scrambled anti-miR or with anti–miR-338-3p and then cultured for 2 days 
in nonadherent dishes to allow them to aggregate in pseudoislet struc-
tures. 500 pseudoislets were transplanted under the left kidney capsule 
of adult Wistar rats. 2 days after transplantation, the rats were injected 
with BrdU (100 mg/kg i.p.). The day after, animals were sacrificed, and 
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